ARTV — Artiva Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $59.45m
- -$125.82m
- $0.25m
- 34
- 28
- 15
- 14
Annual income statement for Artiva Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 2 | 4.93 | 33.5 | 0.251 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 18.3 | 55.3 | 64.8 | 64.2 | 67.5 |
| Operating Profit | -18.3 | -53.3 | -59.8 | -30.7 | -67.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -18 | -71.8 | -58.7 | -28.6 | -65.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -18 | -71.8 | -58.8 | -28.7 | -65.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -18 | -71.8 | -58.8 | -28.7 | -65.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -18 | -71.8 | -58.8 | -28.7 | -65.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.773 | -3.09 | -2.53 | -1.23 | -5.81 |